262375-99-5

Basic information

• Product Name: [4-(4-AMINO-PHENYL)-PIPERAZIN-1-YL]-PHENYL-METHANONE
• Synonyms: TIMTEC-BB SBB009821;ASISCHEM Z44350;ART-CHEM-BB B025575;AKOS BB-8550;[4-(4-AMINO-PHENYL)-PIPERAZIN-1-YL]-PHENYL-METHANONE;4-(4-benzoylpiperazin-1-yl)aniline;[4-(4-aminophenyl)-1-piperazinyl]-phenylmethanone;[4-(4-benzoylpiperazin-1-yl)phenyl]amine
• CAS NO: 262375-99-5
• Molecular Formula: C₁₇H₁₉N₃O
• Molecular Weight: 281.35
• Mol File: 262375-99-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [4-(4-AMINO-PHENYL)-PIPERAZIN-1-YL]-PHENYL-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(4-AMINO-PHENYL)-PIPERAZIN-1-YL]-PHENYL-METHANONE(262375-99-5)
• EPA Substance Registry System: [4-(4-AMINO-PHENYL)-PIPERAZIN-1-YL]-PHENYL-METHANONE(262375-99-5)

Safety Data

• Hazardous Substances Data: 262375-99-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[4-(4-amino-phenyl)-piperazin-1-yl]-phenyl-methanone is used as a research compound for its potential as a serotonin modulator, which may have applications in the treatment of mood disorders, anxiety, and depression.
Used in Neuroscience Research:
[4-(4-amino-phenyl)-piperazin-1-yl]-phenyl-methanone is used as a research compound for its potential antipsychotic and analgesic properties, contributing to the understanding and development of treatments for psychiatric disorders and pain management.
Used in Drug Development:
The chemical structure and properties of [4-(4-amino-phenyl)-piperazin-1-yl]-phenyl-methanone make it a promising candidate for further research and development in the pharmaceutical industry, particularly for the creation of new drugs targeting various neurological and psychiatric conditions.

Upstream product

• 16324-55-3 [4-(4-nitro-phenyl)-piperazin-1-yl]-phenyl-methanone 
• 13754-38-6 N-Benzoylpiperazine 
• 636-98-6 p-nitrobenzene iodide 
• 350-46-9 4-Fluoronitrobenzene 
• 182618-86-6 tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate 
• 6269-89-2 1-(4-Nitrophenyl)piperazine 

Downstream Products

• 1594853-50-5 (4-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)piperazin-1-yl)(cyclohexyl)methanone 
• 857580-95-1 N-(4-(4-benzoylpiperazin-1-yl)phenyl)benzamide 

Relevant articles and documents

Phenylpiperazine type UBE2F small molecule inhibitor and synthesis method thereof

The invention discloses a phenylpiperazine type UBE2F small molecule inhibitor and a synthesis method thereof, discloses a phenylpiperazine type compound represented by the general formula I or a pharmaceutically acceptable salt thereof, and further discloses a synthesis route of the general formula I and a synthesis method of each step. As a small molecule inhibitor target at UBE2F, that phenylpiperazine type compound of the present invention effectively suppresses the growth of tumor cell by preventing the G2/M process of cell cycle and inducing apoptosis of human tumor cells. Therefore, thecompound is a new class of specific anti-tumor drugs by targeting UBE2F.

Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents

A series of alkyl/aryl/heteroaryl piperazine derivatives (37-54) were designed and synthesized as potential anticonvulsant agents. The target compounds are endowed with satisfactory physicochemical as well as pharmacokinetic properties. The synthesized compounds were screened for their in vivo anticonvulsant activity in maximal electroshock (MES) and subcutaneous pentylenetetrazole (sc-PTZ) seizure tests. Further, neurotoxicity evaluation was carried out using rotarod method. Structure activity relationship studies showed that compounds possessing aromatic group at the piperazine ring displayed potent anticonvulsant activity. Majority of the compounds showed anti-MES activity whereas compounds 39, 41, 42, 43, 44, 50, 52, and 53 exhibited anticonvulsant activity in both seizure tests. All the compounds except 42, 46, 47, and 50 did not show neurotoxicity. The most active derivative, 45 demonstrated potent anticonvulsant activity in MES test at the dose of 30 mg/kg (0.5 h) and 100 mg/kg (4 h) and also delivered excellent protection in sc-PTZ test (100 mg/kg) at both time intervals. Therefore, compound 45 was further assessed in PTZ-kindling model of epilepsy which is widely used model for studying epileptogenesis. This compound was effective in delaying onset of PTZ-evoked seizures at the dose of 5 mg/kg in kindled animals and significantly reduced oxidative stress better than standard drug phenobarbital (PB). In result, compound 45 emerged as a most potent and safer anticonvulsant lead molecule.

Functionalized acridin-9-yl phenylamines protected neuronal HT22 cells from glutamate-induced cell death by reducing intracellular levels of free radical species

The in vitro neuronal cell death model based on the HT22 mouse hippocampal cell model is a convenient means of identifying compounds that protect against oxidative glutamate toxicity which plays a role in the development of certain neurodegenerative diseases. Functionalized acridin-9-yl-phenylamines were found to protect HT22 cells from glutamate challenge at submicromolar concentrations. The Aryl1-NHAryl2 scaffold that is embedded in these compounds was the minimal pharmacophore for activity. Mechanistically, protection against the endogenous oxidative stress generated by glutamate did not involve up-regulation of glutathione levels but attenuation of the late stage increases in mitochondrial ROS and intracellular calcium levels. The NH residue in the pharmacophore played a crucial role in this regard as seen from the loss of neuroprotection when it was structurally modified or replaced. That the same NH was essential for radical scavenging in cell-free and cell-based systems pointed to an antioxidant basis for the neuroprotective activities of these compounds.

Functionalized acridin-9-yl phenylamines protected neuronal HT22 cells from glutamate-induced cell death by reducing intracellular levels of free radical species

The in vitro neuronal cell death model based on the HT22 mouse hippocampal cell model is a convenient means of identifying compounds that protect against oxidative glutamate toxicity which plays a role in the development of certain neurodegenerative diseases. Functionalized acridin-9-yl-phenylamines were found to protect HT22 cells from glutamate challenge at submicromolar concentrations. The Aryl1-NH-Aryl2 scaffold that is embedded in these compounds was the minimal pharmacophore for activity. Mechanistically, protection against the endogenous oxidative stress generated by glutamate did not involve up-regulation of glutathione levels but attenuation of the late stage increases in mitochondrial ROS and intracellular calcium levels. The NH residue in the pharmacophore played a crucial role in this regard as seen from the loss of neuroprotection when it was structurally modified or replaced. That the same NH was essential for radical scavenging in cell-free and cell-based systems pointed to an antioxidant basis for the neuroprotective activities of these compounds.